Early Access in Oncology: Why Is It Needed?-Reference-Cited by-同舟云学术

Early Access in Oncology: Why Is It Needed?

Published:2019-01 Issue: Volume:2019 Page:228424031985707
ISSN:2284-2403
Container-title:Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
language:en
Short-container-title:Global & Regional Health Technology Assessment

Author:

Apolone Giovanni¹,Ardizzoni Andrea²,Buzzetti Giuliano³^ORCID,Clerico Mario Alberto⁴,Conte Pierfranco⁵,de Braud Filippo¹,De Lorenzo Francesco⁶,Ferrandina Maria Gabriella⁷,Genazzani Armando⁸,Gori Stefania⁹,Maio Michele¹⁰,Patroncini Mauro¹¹,Perrone Francesco¹²,Scambia Giovanni⁷,Scroccaro Giovanna¹³

Affiliation:

1. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italia

2. Policlinico Sant’Orsola-Malpighi, Bologna, Italia

3. Consulta Prevenzione Rischio Cardiovascolare, Dephaforum S.r.l., Milano, Italia

4. Presidente CIPOMO

5. Rete Oncologica Veneta, Padova, Italia

6. European Cancer Patient Coalition, Bruxelles, Belgio

7. Fondazione Policlinico Universitario A. Gemelli, Roma, Italia

8. Università degli Studi del Piemonte Orientale, Novara, Italia

9. Presidente AIOM, Ospedale Sacro Cuore Don Calabria, Negrar (Verona), Italia

10. Azienda Ospedaliera Universitaria Senese, Siena, Italia

11. Dephaforum S.r.l., Milano, Italia

12. Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli, Italia

13. Direzione Farmaci, Dispositivi medici e Protesica, Area Sanità e Sociale, Regione Veneto, Venezia, Italia

Funder

Dephaforum S.r.l.

Publisher

Aboutscience Srl

Subject

Health Policy

Link

http://journals.sagepub.com/doi/pdf/10.1177/2284240319857072

Reference4 articles.

1. Osservatorio Nazionale sull’Impiego dei Medicinali O. L’uso dei farmaci in Italia. Rapporto nazionale 2017. Rome: Agenzia Italiana dei Farmaci, 2018, p. 89.

2. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

3. ESMO-Magnitude of Clinical Benefit Scale version 1.1

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to shorten the market entry innovation in a highly regulated market. The case of Early access programs in the pharmaceutical industry;International Entrepreneurship and Management Journal;2023-10-04

2. Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case;Journal of Pharmaceutical Policy and Practice;2023-05-17

3. Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness;Global & Regional Health Technology Assessment;2022-10-05

4. Skip pattern approach toward the early access of innovative anticancer drugs;ESMO Open;2021-08